Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRIS NASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.43-3.7%$0.54$0.42▼$3.13$16.78M3.05510,937 shs154,278 shsINMBINmune Bio$1.22-0.4%$1.37$1.09▼$11.64$32.30M1.03409,291 shs206,088 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris-4.89%-11.02%-20.30%-55.73%-81.75%INMBINmune Bio-1.61%-14.08%-14.69%-14.08%-84.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.43-3.7%$0.54$0.42▼$3.13$16.78M3.05510,937 shs154,278 shsINMBINmune Bio$1.22-0.4%$1.37$1.09▼$11.64$32.30M1.03409,291 shs206,088 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris-4.89%-11.02%-20.30%-55.73%-81.75%INMBINmune Bio-1.61%-14.08%-14.69%-14.08%-84.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 1.67Reduce$17.003,817.05% UpsideINMBINmune Bio 2.17Hold$8.00558.44% UpsideCurrent Analyst Ratings BreakdownLatest CRIS and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026CRISCuris Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026CRISCuris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/20/2026CRISCuris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.003/11/2026INMBINmune Bio Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$9.44M1.79N/AN/A$0.42 per share1.03INMBINmune Bio$50K645.89N/AN/A$0.88 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$7.58M-$1.19N/AN/AN/A-80.29%N/A-181.57%8/4/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)Latest CRIS and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CRISCuris-$0.3267-$1.25-$0.9233-$1.25$1.69 millionN/A5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/A3/30/2026Q4 2025INMBINmune Bio-$0.27-$0.18+$0.09-$0.18($0.01) millionN/A3/19/2026Q4 2025CRISCuris-$0.4325-$0.50-$0.0675$1.23$3.25 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A1.111.11INMBINmune BioN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipCRISCuris5.42%INMBINmune Bio21.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6038.98 million36.87 millionNo DataINMBINmune Bio1026.58 million20.90 millionOptionableCRIS and INMB HeadlinesRecent News About These CompaniesINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialJune 2, 2026 | globenewswire.comINMB Share News TodayMay 19, 2026 | uk.investing.comINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformMay 15, 2026 | globenewswire.comINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseMay 14, 2026 | globenewswire.comINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointMay 13, 2026 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call TranscriptMay 10, 2026 | insidermonkey.comINmune Bio (INMB) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comINmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 8, 2026 | seekingalpha.comINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform ...May 7, 2026 | caledonianrecord.comCINmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateMay 7, 2026 | globenewswire.comINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory DiseasesMay 5, 2026 | globenewswire.comINmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thApril 30, 2026 | globenewswire.comINmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer ModelsApril 16, 2026 | markets.businessinsider.comINMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comINmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash WiselyApril 1, 2026 | finance.yahoo.comINmune Bio, Inc.: INmune Bio Inc. Announces 2025 Results and Provides Business UpdateMarch 31, 2026 | finanznachrichten.deINmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMarch 31, 2026 | finance.yahoo.comINmune Bio Inc. (INMB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comINmune Bio Inc. Announces 2025 Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comQuant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lagMarch 29, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRIS and INMB Company DescriptionsCuris NASDAQ:CRIS$0.43 -0.02 (-3.74%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.00 (+0.37%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.INmune Bio NASDAQ:INMB$1.22 -0.01 (-0.41%) Closing price 04:00 PM EasternExtended Trading$1.22 +0.00 (+0.41%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
